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Dual Effects of MLS Antibiotics: Transcriptional
Modulation and Interactions on the Ribosome
and 23S rRNA molecules [6–8]. These studies provided
conclusive evidence for rRNA molecules as the key func-
tional components of the ribosome in the process of
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resistance patterns and certain synergistic and antago-Canada
2 Department of Microbiology and nistic interactions [9], which showed that they act at
the peptidyltransferase center (PTC) of the 50S subunit;Infectious Disease
University of Calgary binding involves domains II and V of the 23S rRNA,
blocking peptide bond formation in subtly different waysCalgary, Alberta
Canada [10–12]. Ribosomal proteins also play roles in MLS bind-
ing, presumably by influencing rRNA folding and struc-
ture [13, 14]. Recent high-resolution X-ray analyses have
shown that the macrolide members of this family inter-Summary
fere principally with the transit of the newly synthesized
polypeptide chain through the peptide exit channel ofThe macrolide-lincosamide-streptogramin (MLS) anti-
the ribosome [15, 16].biotics are an important group of translation inhibitors
Clinically, the MLS antibiotics are used primarily forthat act on the 50S ribosome. We show that, at subin-
the treatment of a variety of Gram-positive infections,hibitory concentrations, members of the MLS group
especially methicillin-resistant staphylococci [17]. Themodulate specific groups of bacterial promoters, as
increasing appearance of MLS-resistant strains hasdetected by screening a library of promoter-luxCDABE
compromised these applications in recent years, andreporter clones of Salmonella enterica serovar Typhi-
as a result many synthetic derivatives of the macrolidesmurium. The patterns of transcription permit identi-
have been made [18]. New and improved variants withfication of classes of promoters having differential
enhanced stability and pharmacokinetic behavior haveresponses to antibiotics of related structure and
been developed for the treatment of a variety of emerg-mode-of-action; studies of antibiotic synergy or antag-
ing bacterial infections, including Helicobacter pylori;onism showed that eukaryotic translation inhibitors
macrolide antibiotics also have favorable activity in alle-may act on the 50S ribosome. The mechanism of tran-
viating bacterial infections associated with cystic fibro-scriptional modulation is not known but may involve
sis [19–21].bacterial stress responses and/or the disturbance and
Use of libraries of promoter-lux fusion constructionssubsequent compensation of metabolic networks as
has shown that most antibiotics demonstrate typicala result of subtle interference with ribosome function.
hormetic responses [22]. At subminimal inhibitory con-Transcriptional patterns detected with promoter-lux
centrations (sub-MIC) these compounds may modulateclones provide a novel approach to antibiotic discov-
the transcription of some 5%–10% of bacterial genesery and mode-of-action studies.
in the cell, often inducing 10- to 100-fold up- or downreg-
ulatory responses, with only limited effects on growth.
Introduction At higher concentrations the compounds exhibit their
well characterized inhibitory or cidal activities through
Antibiotics are naturally occurring organic molecules of target-related responses, with few transcription changes
low molecular weight (3000 D) that have been isolated [23]. Antibiotics of dissimilar structural classes and
by virtue of their ability to inhibit (or kill) living organisms; modes of action affect different groups of promoters.
in most cases they act by binding to specific cellular Thus, inhibitors of specific steps involved in the complex
targets [1]. It is estimated that tens of thousands of such process of translation modulate the activity of distinct
molecules have been isolated from bacteria, fungi, and sets of promoters, presumably due to their interaction
plants since the beginning of the antibiotic era (around with different sites within the ribosome. Our previous
1950); the major source has been the Streptomycetes studies indicated that different classes of inhibitors
[2]. A significant number of antibiotics target the bacte- of 30S or 50S function might be distinguished in this
rial ribosome, and two major classes have been identi- way [23].
fied by their ability to bind and interfere with the function Since the promoters affected at sub-MIC depend to
of either the 30S or 50S subunits during translation [3–5]. a large extent on the nature of the antibiotic class being
In recent years, genetic analysis, chemical foot-printing, used, it seems likely that in each case only transcripts
nuclear magnetic resonance, and X-ray crystallography associated with particular metabolic networks are af-
have permitted high-resolution studies of antibiotic- fected. The MLS antibiotics provide a good test for this
ribosome interactions, and specific binding sites have proposition. Since the early work of Vazquez it has been
been defined at the level of single nucleotides in 16S known that these structurally different molecules (Figure
1) act at nearby or overlapping sites on the 50S ribo-
some, as manifested by synergistic or competitive bind-*Correspondence: jed@interchange.ubc.ca
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Figure 1. The Structural Diversity of the MLS Antibiotics
ing to ribosomes and cross-resistance patterns of bac- up or down by one or more of the five antimicrobials.
These positive hits were rescreened, and 193 were se-terial mutants, and have subtle differences in mode of
action and interaction [4]. We demonstrate that antibi- lected for an additional overnight rescreen, which identi-
fied 169 clones giving a consistent response (3-fold acti-otic-induced transcription patterns provide a conve-
nient method to discriminate between members of the vated or repressed). The distribution of upregulated and
downregulated clones identified with the different MLSMLS family and related inhibitors, by providing activity
“fingerprints” or “signatures” for the peptidyltransferase antibiotics is summarized in Table 1.
and peptide exit tunnel inhibitors. We suggest that the
analysis of sub-MIC-induced transcription patterns Comparison of Transcription Responses
could provide the basis for high-throughput screens to among Different Antibiotics
identify novel inhibitory compounds with defined modes To investigate further the changes in transcription pat-
of action. The luxCDABE reporter system is especially terns, luminescence responses from the primary screen-
effective for such assays [24, 25], which could be used ing were reanalyzed to compare directly the activities
with crude mixtures containing low concentrations of of any two different compounds. These data were ob-
bacterial metabolites, since alterations in lux gene ex- tained by taking the log10 of the ratio of the values from
pression can be detected with very high sensitivity in the control (LB) and experimental (LB plus antibiotic)
liquid or on solid culture media. groups. In those cases where the ratio was greater than
zero, the antibiotic-treated group produced stronger lu-
minescence than the control group. When less thanResults
zero, the antibiotic-treated group had reduced lumines-
cence compared to the control group. The collectedScreening the Promoter-lux Reporter Library
with MLS Antibiotics values obtained from each antibiotic treatment were
then plotted against a reference antibiotic for compari-A 6500 clone library of promoter-lux S. typhimurium
constructs [23, 26] was used to monitor transcriptional son purposes. Each data point represents the activities
of a single clone in response to two separate antimicro-changes in the bacterial host on exposure to subinhibi-
tory concentrations of different MLS antibiotics. The bials. For example, in Figure 2B, coordinates (1, 0.5)
represent clones that are more strongly activated by thetranscriptional profile of S. typhimurium in response to
a subinhibitory concentration of azithromycin is shown reference azithromycin (on the X-axis) than by pristina-
mycin (on the Y-axis). Results with different antibioticsin Figure 2A. Each data point represents the response of
a single clone from the library. Points above the diagonal were plotted and the relative distributions can serve
as response signatures for each drug. Thus, when theindicate upregulated clones, those below are downregu-
lated. transcription profile of azithromycin was plotted against
the profile of pristinamycin, most of the points wereAfter the initial screening, a total of 589 clones from
the library were found to be at least 3-fold modulated scattered, with subpopulations located in sectors repre-
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Figure 2. Identification and Analysis of MLS-Modulated lux-Promoter Clones
(A) Scatter plot showing luminescence in response to azithromycin at 1 g/ml, measured in counts per second (cps), plotted against response
without antibiotic, determined using a 6500-clone S. typhimurium random promoter-lux library, incubated in microtiter plate liquid cultures
for 22 hr at 37C. Points above the diagonal indicate promoter-activated strains and below the diagonal, clones in which promoter activity
was repressed.
(B) Scatter plot of pristinamycin activity (1.25 g/ml) against azithromycin (1 g/ml) after 22 hr, determined using the S. typhimurium library.
Activity calculated from log10 of luminescence of antibiotic-treated cultures over luminescence in LB without antibiotic.
(C) Combined scatter plot of the response to pristinamycin (1.25 g/ml) incubated 22 hr, lincomycin (6.25 g/ml) incubated 24 hr, tylosin (6.25 g/
ml) incubated 24 hr, and telithromycin (1.25 g/ml) incubated 21 hr against azithromycin; results from 196 MLS responsive clones were used.
(D) Luminescence response curves of MLS sensitive- and resistant- (permC) pilvL/G-lux S. typhimurium grown in the presence of azithromycin
at 1.25 g/ml (, –), at 2.5 g/ml (, ), and in the absence of antibiotic (, ).
senting higher levels of activation and repression by of unique promoter-dependent responses were identi-
fied. When the results comparing other MLS antibioticsazithromycin compared to pristinamycin. Overall, the
results show that azithromycin at 0.31 g/ml induces were compiled in the same way, distinct spectra of pro-
moter-modulation activity for each antibiotic becamemore potent induction or repression of certain promot-
ers than pristinamycin at 1.25g/ml; however, a number readily apparent (Figure 2C). For example, telithromycin,
Table 1. S. typhimurium Clones Activated/Repressed by Different MLS Antibiotics
Drugs Classes Activated Repressed Total
Erythromycin 14-membered Macrolide 62 37 99
Azithromycin 15-membered Macrolide 60 32 92
Tylosin 16-membered Macrolide 58 42 100
Telithromycin Ketolide 92 34 126
Pristinamycin Streptogramin 73 37 110
Lincomycin Lincosamide 64 48 112
All 6 antibiotics 12 9 21
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Table 2. Identification of Active Library Clones Responding to Different MLS Antibiotics
Gene Erythromycin Azithromycin Telithromycin Tylosin Lincomycin Pristinamycin Description
STM1547   putative mar-R family
transcriptional regulator
STM1678   putative 2-hydroxylisoflavone
reductase
ybeL       putative cytoplasmic protein
cpxA        sensory kinase in 2-component
regulatory system with CpxR
yfcY      putative acetyl-CoA
acetyltransferase
yrbC  putative ABC superfamily transport
protein
yedO   putative 1-cyclopropane-
carboxylate deaminase
marT    putative transcriptional regulator
MarT
STM1560    putative alpha amylase
yqjA    putative DedA family, membrane
protein
fadL      transport of long-chain fatty acids
STM4316    putative cytoplasmic protein
a ketolide, clearly has a pattern similar, but distinct from, mid encoding an ermC gene under the control of the
tac promoter and inducible by IPTG [18] that confersthe related 14- and 16-membered macrolides; it shows
similarities to the transcriptional response of lincomycin, resistance to certain macrolides by methylation of A2058
in domain V of the 23S rRNA [29]. The ermC-containingwhich might suggest some congruence in 23S rRNA
binding sites. lux-reporter strains showed reductions in transcriptional
activation caused by erythromycin and its close struc-
tural relatives (e.g., clarithromycin or azithromycin) (Fig-Identification of Signature Promoter Sequences
ure 2D). On the other hand, macrolide derivatives thatMLS-activated promoter inserts were PCR amplified
possess a secondary binding site on 23S rRNA, suchand their nucleotide sequences determined. The results
as telithromycin, still elicited a transcription response(Table 2) indicate that promoters for different genes vary
in erythromycin-resistant hosts.in their sensitivity to MLS-modulation (with responses
ranging from 3 to 100) and that the MLS compounds
modulate different transcripts with significant overlap. Responses to Other 50S Subunit Inhibitors
In addition to the MLS, there are a number of antibioticsThis promoter sequence information did not reveal any
patterns of functional metabolic clustering associated with diverse structures with similar modes of action
binding to the 50S ribosome to block translation. The 169with the different antibiotic classes. A significant number
of the promoter responses were S. typhimurium genes MLS-active promoter-lux S. typhimurium clones were
screened against these antibiotics and representativeof unknown function. Thus, discernable antibiotic signa-
tures were identified, but they do not appear to be asso- transcription/modulation results are shown in Table 3.
As expected, considerable differences in promoter re-ciated with any specific biochemical networks, such as
the well characterized stress responses. sponses were observed. The resolving power of the lux-
reporter response effectively discriminates between 50S
inhibitors acting at different target sites on the ribosome.Transcriptional Responses
Some promoter-lux constructs had broad-spectrum re-in MLS-Resistant Strains
sponses (tsr) while others had very limited responsesClinically significant resistance to the MLS antibiotics
(ybfE). Two antibiotics acting specifically on the 60Shas been known for some time; mutations in the bacte-
ribosome of eukaryotic cells, anisomycin and cyclohexi-rial chromosome or the acquisition of resistance plas-
mide, were included in this screening. Anisomycin at amids/transposons can lead to a number of resistance
high concentration (200 g/disc) elicited a weak lumi-phenotypes [20]. Cross-resistance between the MLS
nescence response with the ptsr-lux construct (with nocompounds (the MLSB phenotype) is common, and the
effect on growth of the bacteria). On the other hand,early studies of Vazquez and collaborators [28] provided
cycloheximide had no detectable activity. However,the first convincing evidence that this class of com-
both eukaryotic inhibitors were found to influence tran-pounds interacts at overlapping site(s) on the 50S ribo-
scription effects when used in combination with MLSsome at the PTC. We tested MLS-resistant strains for
antibiotics (see below.)their response to subinhibitory antibiotic concentrations
to establish that transcription modulation requires known
ribosome binding sites. Studies with macrolide-resistant Interactions between Inhibitors Acting
on the 50S Subunitstrains carrying mutant rplV (L5) and rplD (L22) alleles
showed that ribosome mutations alter MLS responses In the mid-1970s David Vazquez and his collaborators
studied synergistic or antagonistic interactions between[23]. Here we employed S. typhimurium carrying a plas-
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various translation inhibitors [28] as determined by mea-
suring competition (or enhancement) of ribosome bind-
ing using radio-labeled antibiotics; these results were
interpreted in terms of overlapping binding sites on the
50S ribosome. Subsequent work using sensitivity-disc
and tube-dilution studies have demonstrated frequent
synergistic and antagonistic interactions between anti-
biotics; a number of these interactions are of clinical
significance [30]. The lux-reporter strains provide an ex-
quisitely sensitive method for the detection of interac-
tions between MLS antibiotics and other 50S inhibitors.
Some typical experiments are shown in Figure 3: they
reveal a range of interactions between translation inhibi-
tors acting on the 50S ribosome. The mechanisms un-
derlying these interactions are not well defined, and it
is not known if any given interaction illustrates overlaps
in binding sites, allosteric interactions, or some other
biochemical effect. Nonetheless such screening may be
of value in mechanism-of-action studies and in indicat-
ing potential positive or negative effects in the therapeu-
tic use of antimicrobials.
Anisomycin and cycloheximide are considered to be
primarily inhibitors of translation in eukaryotes [31], al-
though some Archaea are susceptible to anisomycin.
Using the more sensitive transcription modulation re-
sponse, we examined the possibility that the eukaryotic
inhibitors might have functional interactions with bacte-
rial inhibitors at the ribosome level. Anisomycin and
cycloheximide were found to have concentration-
dependent effects on activation induced by macrolide
(erythromycin and azithromycin) and ketolide (telithro-
mycin) antibiotics. At high (but noninhibitory) concentra-
tions (100 g/ml), they antagonized the antibacterial
compounds, as indicated by reduced luminescence re-
sponses (not shown). However at lower concentrations
(25 g/ml), anisomycin and cycloheximide markedly en-
hanced the activation of certain promoter fusions by
azithromycin and telithromycin. (Figure 4).
Discussion
Screening for the targeted inhibition of biochemical pro-
cesses in microbes has provided a rich collection of
naturally derived antibiotics that have been the founda-
tion of the success of the pharmaceutical industry in the
treatment of infectious diseases [32]. Mode-of-action
studies began early in the antibiotic era [33] and led to
the identification of a variety of specific macromolecular
targets in bacterial cells. Increasingly sophisticated mo-
lecular studies of antibiotic/ribosome interactions have
provided antibiotics with improved pharmacologic proper-
ties and broadened spectrum of activity (including re-
sistant strains). For these applications, attention was
focused on use of antibiotics at growth-inhibitory con-
centrations.
It has been known for some time that antibiotics at
sub-MIC have diverse physiological effects on bacteria
and their eukaryotic hosts [34]; however, such activities
were considered to be secondary issues in the therapeu-
tic use of antibiotics (for example, the post-antibiotic
effect [35]) and have been largely ignored in mode-of-
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action studies. We have shown that subinhibitory con-
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Figure 3. Use of pilvL/G-luxCDABE S. typhimurium to Identify Interactions (Synergy and Antagonism) between MLS Antibiotics and Other 50S
Inhibitors
Virginiamycin, (V), telithromycin (T), erythromycin (E), sparsomycin (S), blasticidin (B), tylosin (TY), hygromycin A (H), pristinamycin IA (P1),
pristinamycin IIA (P2) and pristinamycin complex (P).
Top row of each panel: luminescence from each plate has been converted to the scale indicated on the right, white being high lux expression
and dark blue being low lux expression. Antagonistic interactions are indicated by arrows.
(I) Antagonism between (V) and (T) appears as a flattening between the (V) ring and the (T) ring.
(II and III) Antagonism between (T) and (E) is shown as a flattening between the (E) ring and the (T) rings. Synergy between (V) and (E) is seen
by fusing of the (E) ring with the (V) rings.
(IV) Antagonism between (TY), (H), and (S) is shown by semicircular reductions of the (S) ring caused by (TY) and (H).
(V) Synergy between (S) and (B) causes fusion of the two rings.
(VI and VII) Synergies between (B), (S), and (E) are shown by fusions of the rings.
(VIII) Synergies between (P1), (P2), (P), and (E) cause fusion of the four rings to form a leaf-shaped luminescence pattern.
centrations of antimicrobials modulate global cellular acting principally with the polypeptide exit tunnel and
influencing peptide egress from the ribosome. Differentmetabolism by fine-tuning the activity of different sets
of promoters that are related to antibiotic function. The macrolides (14-, 15-, 16-membered rings) interact with
other domains in the 23S rRNA that may enhance bind-fact that different antibiotics activate or repress different
groups of promoters provides a novel approach to the ing. For example, telithromycin, which is active on some
erythromycin-resistant strains, interacts with A2508 (do-identification of classes of antibiotics and their mode of
action. Transcription modulation thus proves to be a main V) and with the loop of helix 35 of the 23S RNA
[38, 39]. The MLS component lincomycin binds to themore sensitive test of small molecule activity than
growth inhibition. PTC but directly inhibits peptide bond formation,
whereas the streptogramins (pristinamycin) interfereAmong the most valuable and widely used antibiotics
are the macrolides that inhibit bacterial protein synthesis with peptide export.
The transcription-modulating effects of the differentby interfering with the peptide exit tunnel function on
the 50S ribosome. Erythromycin is the oldest of these classes of macrolides allow fine discrimination between
their structural analogs; defined panels of promoter/compounds, and its related chemically modified deriva-
tives dominate the therapeutic market [21, 36]. Extensive reporter fusions have utility in antibiotic discovery and
identification, to assign antibiotics with unknown modestudies of macrolide binding to the 50S subunit, em-
ploying cross-linking, fingerprinting, nuclear magnetic of action to specific classes, for example. Screening
can be carried out directly with crude cell supernatantsresonance, and more recently high-resolution crystallo-
graphic studies, have revealed the interactions de- or extracts of producing strains in a high-throughput
manner, thereby distinguishing inhibitors with noveltermining the functional binding of macrolides (and other
MLS antibiotics) to a small number of sites in the 23S modes of action from known compounds at an early
stage of the drug discovery process. Since the pro-rRNA. The most important interaction is with base
A2508, which was first indicated from studies of MLS- moter/reporter constructs vary in their responses de-
pending on the promoter, bacterial host, and cultureresistant bacteria [11, 15, 19, 37]. All macrolides bind
to the same site on the ribosome within the PTC, inter- medium (minimal or rich, solid or liquid), panels could
Dual Effects of MLS Antibiotics
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Figure 4. The Effect of Anisomycin and
Cycloheximide on Luminescence Induced by
Erythromycin (E), Telithromycin (T), and Azi-
thromycin (A)
Filter discs containing the antibiotics were
placed on lawns of pilvL/G (I–III) and ptsr (IV–
VI) S. typhimurium. Plates I and IV: LB; II and
V: LB plus 25 g/ml of cycloheximide; III and
VI: LB plus 25 g/ml of anisomycin. Top row
of each panel: luminescence produced from
each plate has been converted to the scale
indicated on the right, white being high lux
expression and dark blue being low lux ex-
pression.
On LB alone (I), although there is an inhibition
zone around (T), only (E) induces lux expres-
sion; (A) and (T) do not induce lux expression.
With cycloheximide (II) and anisomycin (III)
added to the LB, (A) is upregulated compared
to LB alone (I). Similarly, the response of ptsr
to all three drugs (A, T, E) is increased in the
presence of cycloheximide (V) and aniso-
mycin (VI) compared to no antibiotics (IV).
be designed to discriminate between compounds on scription signatures for a variety of antibiotic classes
[42–45]. Using DNA bacterial arrays, these workers havethe basis of mode of action or structural class. Very
low concentrations of both Gram-negative and Gram- tested MIC or higher concentrations of antibiotics and
found a range of transcription modulation more limitedpositive active compounds can be detected, even when
using a Gram-negative screening host; employing hy- than what is reported here. In addition, earlier studies
did not report the in-depth examination of an antibioticpersensitive hosts [40] would enhance this capability.
Nonetheless, reporter libraries developed with Gram- class such as MLS. In several instances only stress
responses were detected. Our studies confirm the valuepositive hosts such as Staphylococcus aureus would
be essential to examine the full spectrum of all antibiotic of transcription modulation induced by antibiotics as a
simple experimental approach to discriminating be-activities.
Comparisons of the use of promoter-lux fusions to tween structurally different inhibitors of translation.
The mechanism of antibiotic-induced transcriptionidentify functional interactions between ribosomally ac-
tive antibiotics in vivo may be expedient for mode-of- modulation is not known. We suggest that antibiotics at
sub-MIC bind to their known target sites on the ribosomeaction studies and in the screening of chemically synthe-
sized derivatives; crude reaction products could be (albeit transiently), causing minor perturbations in ribo-
some function. These effects must be responsible for atested rapidly for their activity profiles in the presence
of compounds with known target specificity. 60S (eu- mechanism coupling translation to transcription, re-
sulting in promoter-selective modulations of the latter.karyotic) ribosome inhibitors showed only weak stimula-
tory activity on bacterial lux reporter strains, but they The transmission of signals from ribosome to RNA poly-
merase due to subinhibitory MLS could involve the re-stimulated or antagonized transcription modulation by
MLS antibiotics (Figure 4). This suggests that compounds lease of small amounts of incomplete polypeptides [46],
interference with ribosome assembly [47], induction ofsuch as anisomycin and cycloheximide may interact
functionally with bacterial 50S ribosomes; anisomycin translation errors [48], or possibly interactions of small
molecules with RNA [49]. The sequelae of all theseis known to inhibit protein synthesis in the halobacteria.
From an evolutionary standpoint, this cross-reactivity events may be low-level stress responses that act
through one of the many bacterial sigma factors to acti-would be expected if the ribosomal targets for these
inhibitors were conserved [41]. In any event, these ob- vate or repress specific sets of transcripts [50, 51]. These
changes might also result in compensating effects onservations raise the possibility that even compounds
considered as eukaryotic inhibitors could be used as the transcription of nodes of linked metabolic networks.
It is clear that antibiotic inhibitors (and possibly otherlead molecules in chemical modification programs to
identify novel classes of antibacterial compounds active small molecules) exhibit hormesis, a phenomenon char-
acterized by distinctly different responses at low con-on the 50S ribosome. Similar studies with a selection
of antibiotics that bind to the bacterial 30S ribosome centrations (transcription modulation) compared to high
concentrations (growth inhibition) [22]. We believe thatsubunit are in progress. We note that several groups
have applied comparable approaches to obtain tran- subinhibitory concentrations identify responses that
Chemistry & Biology
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microtiter plates). Salmonella reporter clones were grown aerobi-more accurately reflect antibiotic mode of action and
cally at 37C in solid or liquid LB medium with kanamycin at 50have suggested that these effects might represent the
g/ml to maintain the plasmids.“natural” role of antibiotics, since in the environment
Screening was conducted in 384-well opaque wide plates. A 384-
the concentrations of these molecules rarely attain in- pin replicator was used to inoculate overnight cultures into the wells
hibitory levels [23]. of screening plates containing LB broth with various antibiotics at
a range of subinhibitory concentrations (typically 10-fold lower than
the MIC). Plates were then incubated at 37C and luminescenceSignificance
was measured (at 5 hr and 20 hr) using a Victor II 1420 Multilabel
counter (Perkin-Elmer, Boston, MA). Based on differential expres-
The action of subinhibitory concentrations of antibiot- sion of 3-fold or greater luminescence, positive clones were se-
ics on promoter-lux fusions provides a highly sensitive lected, rearrayed, and vigorously rescreened using the same condi-
tions, with an additional concentration inserted into each antibioticand discriminatory approach for the study and classifi-
tested. Overall, the fall-off rate was 67.2% for the first screen andcation of protein synthesis inhibitors. Transcriptional
12.4% for the second screen. To obtain more detailed profiles of theeffects detected with selected promoter fusions pro-
response of the clones to specific antibiotics, they were rescreenedvide gene expression “signatures” and permit the
again in an overnight assay with continuous hourly monitoring.
identification of compounds on the basis of mode of Characterization of promoter inserts in active clones was done
action. by PCR-amplification and sequencing of insert DNA fragments using
vector primers pCSFor (5-TGGCAATTCCGACGTCTAAG-3) andInteractions between different structural and func-
pCSRev (5-CACTAAATCATCACTTTCGG-3). Sequencing was per-tional classes of antibiotics can be readily detected
formed by Certigen (Lubbock, TX). The promoters were identified byin vivo, and both synergies and antagonisms are com-
comparison with the GenBank database using the standard BlastNmon. Studies with combinations of antibiotics showed
program (NCBI), then analyzed using VECTOR NTI software (In-
that inhibitors of translation in eukaryotic cells altered formax, Bethesda, MD).
the transcriptional activity of antibacterial antibiotics.
This is consistent with the evolutionary relationships Solid Media Assay
between ribosome structures, indicating that antibi- Overnight LB cultures from single colonies of reporter strains were
diluted 1000-fold and inoculated into 0.7% agar (containing kanamy-otic target sites are conserved between kingdoms
cin); appropriate dilutions were made into soft agar and overlaid on[41]. The implications for the evolution of natural anti-
LB plates. EtestR strips (AB Biodisk, Solna, Sweden) or antibioticbiotic inhibitors of the ribosome are apparent; did
sensitivity discs were placed on top of the overlay. Plates werethese molecules coevolve with the translation system
incubated at 37C overnight and luminescence was detected with
[52]? The interactions between antibiotics which act a Luminograph LB980 photon camera (Berthold Technologies, Bad
on the ribosome, as detected with promoter-lux fu- Wildbad, Germany).
sions, can be employed to identify ribosome-active
compounds that could be of value as lead molecules Assaying the Effects of Antibiotic Resistance
on Transcription Modulationin structure-based chemical modification programs to
Duplicates of 2-fold serial dilutions of MLS antibiotics were madeprovide novel classes of ribosome-targeted antibacte-
in the wells of black clear-bottom 96-well plates. Overnight liquidrial compounds. The eukaryote inhibitors anisomycin
cultures of sensitive reporter strains and reporter strains trans-and cycloheximide might be candidates for just such
formed with pCTermC (a plasmid encoding a tac-regulated erythro-
a program. mycin resistance gene [18, 27]) were diluted 1:100 in LB medium.
The mechanism(s) by which inhibitors of ribosome Isopropylthio--galactoside (IPTG) to a final concentration of 1 mM
was added to all wells, and luminescence was recorded after over-function can modulate a plethora of transcription
night incubation at 37C in the multilabel counter. Other plasmid-events is not known. The ribosome is an extremely
determined resistance mechanisms were used in similar fashion.complex target and has pleiotropic activities; the ef-
Tests were also carried out on solid medium as indicated above. Infect of a translation inhibitor on cell function cannot
some cases, E. coli MG1655 carrying resistance plasmids was used
be easily interpreted. The ease, flexibility, and wide as a host strain to analyze the effect of resistance mechanisms.
dynamic range of promoter-lux reporter libraries per-
mit the identification of unsuspected activities of small Competition Experiments
molecules that may reflect the roles of these mole- Competition experiments were conducted using agar medium
assays. Antibiotic sensitivity discs containing, for example, 15 gcules in the environment.
of erythromycin were placed in the middle of the plate and discs
containing appropriate concentrations of other antibiotics wereExperimental Procedures
placed in close proximity to the central disc; tests at various dis-
placements were necessary. In some cases, one of the antibioticsAntibiotics and Growth Conditions
being tested was incorporated into the agar medium at a subinhibi-Cultures were grown aerobically in Luria-Bertani (LB) medium sup-
tory concentration. Luminescence was monitored using the Lumino-plemented with kanamycin (50 g/ml) at 37C (unless otherwise
graph camera; the shape of the light zone between neighboringnoted). Other antibiotics were added as appropriate. Antibiotics
antibiotics indicated the type of interaction (or lack thereof) betweenwere kindly donated by industry, obtained from Sigma, or taken
the two drugs.from the laboratory collection.
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